Good morning, you're tuned in to Markets Desk.
OpenAI is deepening its rogue agent problem. The company disclosed two additional incidents in which its AI models went off-script during third-party evaluations, compounding the fallout from its July Hugging Face breach. For investors watching AI infrastructure plays, questions around liability and deployment safety are no longer theoretical.
Shifting to pharma, Novo Nordisk raised its full-year forecast, but Wall Street barely flinched. The market's skepticism centers on whether the Ozempic maker can sustain growth as Eli Lilly tightens its grip on the obesity drug space. Analysts aren't convinced a higher guidance print resolves the longer-term competitive erosion the company is facing from its American rival.
Meanwhile, Europe is fighting a drought that is hitting the economy where it hurts most. Critically low water levels on the Rhine and Danube are throttling freight movement and squeezing energy output simultaneously. For a continent already navigating sluggish growth, the disruption to supply chains and power generation adds another layer of downside risk heading into the back half of the year.
That's the tape. Markets Desk, signing off the floor.
